Avecris
Avecris is developing non-viral gene delivery technologies with unprecedented activity and specificity
Avecris is developing non-viral gene delivery technologies with unprecedented activity and specificity
Avecris is a Singapore-based startup founded in 2017, focusing on developing non-viral gene delivery technologies. The company's slogan "Avecris is developing non-viral gene delivery technologies with unprecedented activity and specificity" underscores its commitment to innovation. Avecris's novel genetic vector platform technology is universally programmable, scalable, redosable, non-integrating, cell-type specific, and low cost, positioning it towards a new class of medicines. The company's recent last investment of $5.00K came through a grant investment on 10 August 2022, with First Flight Venture Center as the investors. With its promising technology and strategic location, Avecris is poised to make a significant impact in the biotech industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $5.00K | 1 |
|
10 Aug 2022 |
| Venture Round | $3.60M | 1 | Alameda Research | 01 Jan 2022 |
No recent news or press coverage available for Avecris.
We care about your data, and we'd love to use cookies make your experience better.